A Strategy Of Success
in the Treatment of Prostate Cancer

PCRI Insights July, 2002 vol. 5, no. 1
By Stephen B. Strum, MD, FACP

Page
<<  1  2  3  

References

1. Batson OV: The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112:138-149, 1940.

2. Steinberg GD, Carter BS, Beaty TH, et al: Family history and the risk of prostate cancer. Prostate 17:337-47, 1990.

3. Brooks JD, Metter EJ, Chan DW, et al: Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166:2034-8, 2001.

4. Clark LC, Combs GF, Jr., Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama 276:1957-63, 1996.

5. Heinonen OP, Albanes D, Virtamo J, et al: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440-6, 1998.

6. Fleshner N, Fair WR, Huryk R, et al: Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 161:1651-4, 1999.

7. Helzlsouer KJ, Huang HY, Alberg AJ, et al: Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92:2018-23, 2000.

8. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277:1452-5, 1997.

9. Crawford ED, Chia D, Andriole G, et al: PSA changes as related to the initial PSA: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Proc Am Soc Clin Oncol 20:177a, 2001.

10. Keetch DW, McMurtry JM, Smith DS, et al: Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 156:428-31, 1996.

11. Chen ME, Troncoso P, Johnston D, et al: Prostate cancer detection: relationship to prostate size. Urology 53:764-8, 1999.

12. Aihara M, Lebovitz RM, Wheeler TM, et al: Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol 151:1558-64, 1994.

13. D'Amico AV, Propert KJ: Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 35:273-9, 1996.

14. D'Amico AV, Chang H, Holupka E, et al: Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 49:385-91, 1997.

15. Stamey TA, McNeal JE, Yemoto CM, et al: Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-400, 1999. 16. Matsushima H, Kitamura T, Goto T, et al: Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 158:2278-83, 1997.

17. Shariat SF, Shalev M, Menesses-Diaz A, et al: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19:2856-64, 2001.

18. Steinberg DM, Sauvageot J, Piantadosi S, et al: Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21:566-76, 1997.

19. Wurzer JC, Al-Saleem TI, Hanlon AL, et al: Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment. Cancer 83:753-9, 1998.

20. Carlson GD, Calvanese CB, Kahane H, et al: Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 51:525-9, 1998.

21. Kronz JD, Silberman MA, Allsbrook WC, et al: A web-based tutorial improves practicing pathologists' Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy: validation of a new medical education paradigm. Cancer 89:1818-23, 2000.

22. Badalament RA, Miller MC, Peller PA, et al: An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 156:1375-80, 1996.

23. Borirakchanyavat S, Bhargava V, Shinohara K, et al: Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy. Urology 50:373-8, 1997.

24. Conrad S, Graefen M, Pichlmeier U, et al: Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 159:2023-9, 1998.

25. D'Amico AV, Whittington R, Malkowicz SB, et al: Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55:572-7, 2000.

26. D'Amico AV, Schultz D, Silver B, et al: The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49:679-84, 2001.

27. Grossfeld GD, Chang JJ, Broering JM, et al: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 165:851-6, 2001.

28. Huland H, Hammerer P, Henke RP, et al: Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized proclinistatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. J Urol 155:1344-7, 1996.

29. Peller PA, Young DC, Marmaduke DP, et al: Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 75:530-8, 1995. 30. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/ recurrent detectable PSA after radical prostatectomy. Urology 44:371-6, 1994.

31. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al: [Role of biological and anatomo-pathologic criteria in the prognosis evaluation of patients before and after radical prostatectomy]. Prog Urol 4:673-82, 1994.

32. Wills ML, Sauvageot J, Partin AW, et al: Ability of sextant biopsies to predict radical prostatectomy stage. Urology 51:759-64, 1998.

33. Ahlgren G, Lindholm K, Falkmer U, et al: A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate. Urology 50:379-84, 1997.

34. Badalament RA, O'Toole RV, Young DC, et al: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 67:3014-23, 1991.

35. Carmichael MJ, Veltri RW, Partin AW, et al: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 153:1015-9, 1995.

36. Currin SM, Lee SE, Walther PJ: Flow cytometric analysis of comedocarcinoma of the prostate: an uncommon histopathological variant of prostatic adenocarcinoma. J Urol 140:96-100, 1988.

37. Erbersdobler A, Hammerer P, Huland H, et al: Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. J Urol 158:1594- 8, 1997.

38. Forsslund G, Esposti PL, Nilsson B, et al: The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 69:1432-9, 1992.

39. Gauwitz MD, Pollack A, el-Naggar AK, et al: The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 28:821-8, 1994.

40. Greene DR, Rogers E, Wessels EC, et al: Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151:1301-7, 1994.

41. Greene DR, Wheeler TM: Clinical relevance of the individual prostate cancer focus. Cancer Invest 12:425-37, 1994.

42. Hawkins CA, Bergstralh EJ, Lieber MM, et al: Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Urology 46:356-64, 1995.

43. Henke RP, Hammerer P, Graefen M, et al: Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. Cancer 83:977-88, 1998.

44. Hussain MH, Powell I, Zaki N, et al: Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer. Cancer 72:3012-9, 1993.

45. Khoo VS, Pollack A, Cowen D, et al: Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41:166-72, 1999.

46. Lee SE, Currin SM, Paulson DF, et al: Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol 140:769-74, 1988.

47. Lerner SE, Blute ML, Bergstralh EJ, et al: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156:137-43, 1996.

48. Lerner SE, Blute ML, Zincke H: Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 14:12- 20; discussion 21, 1996.

49. Miller J, Horsfall DJ, Marshall VR, et al: The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma. J Urol 145:1192-6, 1991.

50. Phillips JL, Hayward SW, Wang Y, et al: The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 61:8143-9, 2001.

51. Pollack A, Zagars GK, el-Naggar AK, et al: Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer 73:1895-903, 1994.

52. Pollack A, Zagars GK, el-Naggar AK, et al: Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 44:711-8, 1994.

53. Ross JS, Figge H, Bui HX, et al: Prediction of pathologic stage and post-prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 74:2811-8, 1994.

54. Ross JS, Figge HL, Bui HX, et al: E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 7:835-41, 1994.

55. Scrivner DL, Meyer JS, Rujanavech N, et al: Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies. J Urol 146:1034-9, 1991.

56. Shankey TV, Jin JK, Dougherty S, et al: DNA ploidy and proliferation heterogeneity in human prostate cancers. Cytometry 21:30-9, 1995.

57. Song J, Cheng WS, Cupps RE, et al: Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol 147:794-7, 1992.

58. Stege R, Tribukait B, Lundh B, et al: Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 148:833-7, 1992.

59. Tinari N, Natoli C, Angelucci D, et al: DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. Cancer 71:1289-96, 1993.

60. van den Ouden D, Tribukait B, Blom JH, et al: Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 150:400-6, 1993.

61. van der Poel HG, Oosterhof GO, Schaafsma HE, et al: Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 49:652-7, 1997.

62. Berruti A, Dogliotti L, Bitossi R, et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164:1248-53, 2000.

63. Koga H, Naito S, Koto S, et al: Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39:1-7, 1999.

64. Takeuchi S, Arai K, Saitoh H, et al: Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 156:1691-5, 1996.

65. Smith MR, McGovern FJ, Fallon MA, et al: Low bone mineral density in hormone- naive men with prostate carcinoma. Cancer 91:2238-45, 2001.

66. Schatzl G, Madersbacher S, Thurridl T, et al: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47:52-8, 2001.

67. Hoffman MA, De Wolf WC, A M: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163:824-7, 2000.

68. Zagars GK, Pollack A, von Eschenbach AC: Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49:327-34, 1997.

69. Kitahara S, Yoshida K, Ishizaka K, et al: Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J 44:527-32, 1997.

70. Oefelein MG, Feng A, Scolieri MJ, et al: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56:1021-4, 2000.

71. Oefelein MG, Cornum R: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164:726-9, 2000.

72. Dattoli M, Wallner K, True L, et al: Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 45:853-6, 1999.

73. Moul JW, Connelly RR, Perahia B, et al: The contemporary value of pre-treatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 159:935-40, 1998.

74. Han M, Piantadosi S, Zahurak ML, et al: Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57:707-11, 2001.

75. Roy AV, Brower ME, Hayden JE: Sodium thymolphthalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 17:1093-1102, 1971.

76. Batuello JT, Gamito EJ, Crawford ED, et al: Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology 57:481-5, 2001.

77. Han M, Snow PB, Epstein JI, et al: A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 56:994-9, 2000.

78. Bostwick DG, Burke HB: Prediction of individual patient outcome in cancer: comparison of artificial neural networks and Kaplan--Meier methods. Cancer 91:1643-6, 2001.

79. Babaian RJ, Fritsche H, Ayala A, et al: Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 56:1000-6, 2000.

80. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinistatic cal stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-4, 1993.

81. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. Jama 277:1445-51, 1997.

82. Partin AW, Mangold LA, Lamm DM, et al: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843-8, 2001.

83. Ziada AM, Lisle TC, Snow PB, et al: Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. Cancer 91:1653-60, 2001.

84. Tewari A, Issa M, El-Galley R, et al: Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol 5:163-9, 2001.

85. Porter C, O'Donnell C, Crawford ED, et al: Artificial neural network model to predict biochemical failure after radical prostatectomy. Mol Urol 5:159-62, 2001.

<<  1  2  3  

 

Prostate Cancer Research Institute (PCRI)

Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.